EUVIMEDEUVIMED entdecken
Crossref

Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survival

Sarit Appel iD, Lee Wilk, Akram Saad, Damien Urban, Hadas Sorotsky, Guy Kalmanovitz, Amir Onn, Ori Haisraeli, Edith M Marom, Yaacov R Lawrence, Jeffery Goldstein, Jair Bar

British Journal of Radiology · 2025

DOI: 10.1093/bjr/tqaf133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, 2025. Verfasst von Sarit Appel und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Benjamin Davidai Department of Radiation Oncology, Sheba Medical Center Tel Hashomer, Ramat Gan, 5262160, Israel. Hauptthemen laut MEDLINE: Lung Neoplasms, Chemoradiotherapy, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Medical Research Education, Sheba Medical Center Tel Hashomer Israel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We hypothesized that pneumonitis during Pacific protocol (PDP) contributes to poor outcomes in patients with locally advanced non-small cell lung cancer (LANSCLC) treated with chemoradiation (ChRT) and durvalumab.

Methods

We analysed cases with LANSCLC extracted from a single academic institution database to identify patient, tumour, and treatment characteristics predicting for development of PDP and its effect on oncologic outcomes.

Results

Our database review identified 119 patients with LANSCLC that were treated with ChRT and durvalumab. Sixty-five percent were male and had a mean age of 66 years (SD 8); 58% stage IIB-IIIA, and 51% adenocarcinoma. PDP occurred in 35 (29.4%) cases, at a mean 2.6 months from durvalumab initiation (range 0.3-11 months), and was mostly low grade: G1-12, G2-18, G3-3, G4-1, G5-1. PDP resulted in treatment interruption in 24 cases (20%) with treatment discontinuation in 17 cases (14.3%). Multivariate analysis (MVA) showed all-grades PDP correlated with tumour stage, ipsilateral lung V5 ≥ 70%, and mean heart dose (MHD) ≥ 6 Gy. Grades 2-5 PDP correlated with total lungs V20 ≥ 27% and MHD ≥ 6 Gy. PDP did not correlate with a history of prior radiation pneumonitis (RP) (9/119). PDP was associated with decreased 3-year local control (LC) and progression-free survival (PFS); LC 53% vs 75.5% (HR 2.15, P = 0.031); PFS 35.5% vs 56.5% (HR 1.8, P = 0.04); and a trend for shorter overall survival (OS; 66% vs 77.5%, HR 1.5, P = 0.27).

Conclusion

PDP correlated with ipsilateral lung V5 ≥ 70%, lungs V20 ≥ 27% and MHD ≥ 6 Gy. PDP was associated with inferior LC and PFS and trended for shorter OS. Advances in knowledge PDP occurred in a third of patients resulting in treatment discontinuation in 14.3%. PDP grades 2-5 correlated with radiation dose to lungs V20 ≥ 27% and MHD ≥ 6 Gy. PDP was associated with inferior LC and PFS and trended for shorter OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsChemoradiotherapyCarcinoma, Non-Small-Cell LungAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalPneumoniaHumansMaleAgedFemaleMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

Pacific protocoldefinitive chemoradiationdurvalumabimmune-related side effectsnon-small cell lung cancerpneumonitis

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • The Benjamin Davidai Department of Radiation Oncology, Sheba Medical Center Tel Hashomer, Ramat Gan, 5262160, Israel.
  • Arrow Program for Medical Research Education, Sheba Medical Center Tel Hashomer, Ramat Gan, 5262160, Israel.
  • Jusidman Cancer Center, Sheba Medical Center Tel Hashomer, Ramat Gan, 5262160, Israel.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Department of Pulmonology, Sheba Medical Center Tel Hashomer, Ramat Gan, 5262160, Israel.
  • Diagnostic Radiology Department, Sheba Medical Center, Ramat Gan, 5262160, Israel.

ORCID-Profile: Sarit Appel

Förderung

  • Medical Research Education
  • Sheba Medical Center Tel Hashomer Israel

Zitieren

APA

Appel, S., Wilk, L., Saad, A., Urban, D., Sorotsky, H., Kalmanovitz, G., Onn, A., Haisraeli, O., Marom, E. M., Lawrence, Y. R., Goldstein, J., & Bar, J. (2025). Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survival. British Journal of Radiology. https://doi.org/10.1093/bjr/tqaf133

Vancouver

Appel S, Wilk L, Saad A, Urban D, Sorotsky H, Kalmanovitz G, et al. Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survival. British Journal of Radiology. 2025. doi:10.1093/bjr/tqaf133

BibTeX
@article{Appel2025,
  author = {Appel, Sarit and Wilk, Lee and Saad, Akram and Urban, Damien and Sorotsky, Hadas and Kalmanovitz, Guy and Onn, Amir and Haisraeli, Ori and Marom, Edith M and Lawrence, Yaacov R and Goldstein, Jeffery and Bar, Jair},
  title = {Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survival},
  journal = {British Journal of Radiology},
  year = {2025},
  doi = {10.1093/bjr/tqaf133}
}
Kostenlos starten →